Loading...

Medical Marijuana

OTCPK:MJNA
Snowflake Description

Mediocre balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MJNA
OTCPK
$208M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Medical Marijuana, Inc., an investment holding company, operates in the medical marijuana and industrial hemp markets. The last earnings update was 19 days ago. More info.


Add to Portfolio Compare Print
  • Medical Marijuana has significant price volatility in the past 3 months.
MJNA Share Price and Events
7 Day Returns
16.1%
OTCPK:MJNA
-1.4%
US Healthcare
-0.7%
US Market
1 Year Returns
-46.4%
OTCPK:MJNA
-2.9%
US Healthcare
3%
US Market
MJNA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Medical Marijuana (MJNA) 16.1% -4.8% -26.5% -46.4% 19.1% -70.2%
US Healthcare -1.4% 4% -11.4% -2.9% 20.1% 59.8%
US Market -0.7% -2% 2.4% 3% 39.2% 42%
1 Year Return vs Industry and Market
  • MJNA underperformed the Healthcare industry which returned -2.9% over the past year.
  • MJNA underperformed the Market in United States of America which returned 3% over the past year.
Price Volatility
MJNA
Industry
5yr Volatility vs Market

MJNA Value

 Is Medical Marijuana undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Medical Marijuana. This is due to cash flow or dividend data being unavailable. The share price is $0.0573.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Medical Marijuana's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Medical Marijuana's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:MJNA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.06
OTCPK:MJNA Share Price ** OTCPK (2019-05-17) in USD $0.06
United States of America Healthcare Industry PE Ratio Median Figure of 56 Publicly-Listed Healthcare Companies 20.6x
United States of America Market PE Ratio Median Figure of 3,088 Publicly-Listed Companies 17.89x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Medical Marijuana.

OTCPK:MJNA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:MJNA Share Price ÷ EPS (both in USD)

= 0.06 ÷ -0.06

-1.01x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medical Marijuana is loss making, we can't compare its value to the US Healthcare industry average.
  • Medical Marijuana is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Medical Marijuana's expected growth come at a high price?
Raw Data
OTCPK:MJNA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.01x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Healthcare Industry PEG Ratio Median Figure of 42 Publicly-Listed Healthcare Companies 1.67x
United States of America Market PEG Ratio Median Figure of 2,117 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Medical Marijuana, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Medical Marijuana's assets?
Raw Data
OTCPK:MJNA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.02
OTCPK:MJNA Share Price * OTCPK (2019-05-17) in USD $0.06
United States of America Healthcare Industry PB Ratio Median Figure of 92 Publicly-Listed Healthcare Companies 2.36x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
OTCPK:MJNA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:MJNA Share Price ÷ Book Value per Share (both in USD)

= 0.06 ÷ 0.02

2.98x

* Primary Listing of Medical Marijuana.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medical Marijuana is overvalued based on assets compared to the US Healthcare industry average.
X
Value checks
We assess Medical Marijuana's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Medical Marijuana has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MJNA Future Performance

 How is Medical Marijuana expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medical Marijuana has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.1%
Expected Healthcare industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Medical Marijuana expected to grow at an attractive rate?
  • Unable to compare Medical Marijuana's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Medical Marijuana's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Medical Marijuana's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:MJNA Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 13.1%
United States of America Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:MJNA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:MJNA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 60 -199 -203
2018-09-30 52 -322 -313
2018-06-30 43 -299 -294
2018-03-31 33 -282 -275
2017-12-31 27 -155 -142
2016-12-31 8 -20 -26

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Medical Marijuana is high growth as no earnings estimate data is available.
  • Unable to determine if Medical Marijuana is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:MJNA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Medical Marijuana Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:MJNA Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.06
2018-09-30 -0.09
2018-06-30 -0.09
2018-03-31 -0.08
2017-12-31 -0.04
2016-12-31 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Medical Marijuana will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Medical Marijuana's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  2. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Medical Marijuana's filings and announcements here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Medical Marijuana's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Medical Marijuana has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MJNA Past Performance

  How has Medical Marijuana performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Medical Marijuana's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Medical Marijuana does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Medical Marijuana's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Medical Marijuana's 1-year growth to the US Healthcare industry average as it is not currently profitable.
Earnings and Revenue History
Medical Marijuana's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Medical Marijuana Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:MJNA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 59.83 -202.63 49.88
2018-09-30 51.59 -313.02 39.19
2018-06-30 42.54 -293.60 34.35
2018-03-31 33.44 -274.57 28.29
2017-12-31 26.52 -142.20 22.94
2016-12-31 8.00 -25.91 8.49
2015-12-31 9.22 25.97 8.61
2015-09-30 9.90 -17.83 8.37
2015-06-30 11.48 -10.12 8.72
2015-03-31 14.07 -5.39 9.32
2014-12-31 14.52 -4.49 8.53
2014-09-30 14.23 4.78 7.61 0.02
2014-06-30 11.41 12.29 5.62 0.02
2014-03-31 7.42 19.26 3.71 0.02
2013-12-31 5.06 24.61 2.66 0.02
2013-09-30 7.79 22.58 2.65
2013-06-30 10.10 15.86 2.67
2013-03-31 11.52 11.27 2.34
2012-12-31 11.64 7.11 1.69

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Medical Marijuana has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Medical Marijuana has efficiently used its assets last year compared to the US Healthcare industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Medical Marijuana improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Medical Marijuana's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Medical Marijuana has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MJNA Health

 How is Medical Marijuana's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Medical Marijuana's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Medical Marijuana is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Medical Marijuana's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Medical Marijuana's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Medical Marijuana Company Filings, last reported 4 months ago.

OTCPK:MJNA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 68.52 16.96 4.36
2018-09-30 89.77 9.32 3.33
2018-06-30 109.94 10.02 3.09
2018-03-31 128.09 11.98 3.46
2017-12-31 259.39 14.84 2.31
2016-12-31 380.80 11.73 1.13
2015-12-31 201.16 13.67 0.27
2015-09-30 116.73 26.37 0.28
2015-06-30 123.28 23.97 18.98
2015-03-31 135.89 26.71 0.79
2014-12-31 137.56 26.62 0.79
2014-09-30 50.93 10.09 33.15
2014-06-30 50.65 12.97 50.44
2014-03-31 46.73 6.88 33.15
2013-12-31 45.26 1.36 30.90
2013-09-30 44.01 0.89 2.04
2013-06-30 34.04 0.00 19.10
2013-03-31 28.55 0.00 14.76
2012-12-31 16.30 0.00 1.42
  • Medical Marijuana's level of debt (24.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (3.1% vs 24.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Medical Marijuana has less than a year of cash runway based on current free cash flow.
  • Medical Marijuana has less than a year of cash runway if free cash flow continues to grow at historical rates of 60.1% each year.
X
Financial health checks
We assess Medical Marijuana's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Medical Marijuana has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MJNA Dividends

 What is Medical Marijuana's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Medical Marijuana dividends.
If you bought $2,000 of Medical Marijuana shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Medical Marijuana's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Medical Marijuana's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:MJNA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 21 Stocks 1.6%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2000 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Medical Marijuana has not reported any payouts.
  • Unable to verify if Medical Marijuana's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Medical Marijuana's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Medical Marijuana has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Medical Marijuana's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Medical Marijuana afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Medical Marijuana has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MJNA Management

 What is the CEO of Medical Marijuana's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Stuart Titus
CEO Bio

Dr. Stuart W. Titus, Ph.D., has been the Chief Executive Officer and President of Medical Marijuana, Inc. since March 18, 2015. Dr. Titus is the Chairman of the board of Director and Acting Chief Financial Officer of Medical Marijuana Inc. He is the Co-founder and serves as President of General Hemp, LLC which with Titus at the helm has managed the emergence and growth of several other companies, including CannaVest, KannaLife Sciences Inc. (Board Member) and KannaWAY. Dr. Titus is an Industry Icon and Innovator, having been involved in all aspects of the medical marijuana and industrial hemp industries, Dr. Titus was the number seven investor in Medical Marijuana, Inc., having invested in its seed financing. Dr. Titus has been involved in the development and investment of several industry-leading cannabis and industrial hemp businesses. Dr. Titus' expertise in finance was forged on Wall Street, where he worked as a bond trader for 11 years, managing a trading and underwriting department as a Vice President for CS First Boston Corp. Dr. Titus also has a unique background in health. Post-Wall Street, he worked as a British Physiotherapist for over 15 years, having run clinics that specialized in integrative pain management and injury rehabilitation, which treated over 40,000 patients. Dr. Titus is active in the medical community with specific interest in electro-physiotherapy as well as in anti-aging medicine. He holds a Fellowship with the American Academy of Pain Management and clinical association with the American Association of Integrative Medicine. Dr. Titus has unique first-hand experience with hemp oil products as nutritional supplements, having found great relief from Lyme's disease symptoms after beginning a regimen of high-concentration CBD therapeutic hemp products. He has been a Director of Medical Marijuana, Inc. since March 18, 2015. Dr. Titus is a graduate of Rollins College in Winter Park, Florida, where he majored in Economics and minored in Business Administration. He earned his Ph.D. degree from the Open International University, which is a World Health Organization (WHO) chartered affiliate.

CEO Compensation
  • Insufficient data for Stuart to compare compensation growth.
  • Insufficient data for Stuart to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure of the Medical Marijuana management team in years:

1.4
Average Tenure
  • The average tenure for the Medical Marijuana management team is less than 2 years, this suggests a new team.
Management Team

Stuart Titus

TITLE
Chairman of the Board

Blake Schroeder

TITLE
COO & Executive VP
AGE
40
TENURE
1.4 yrs

Dirk Syburra

TITLE
Vice President of Data & Technology
TENURE
2.3 yrs

Nicholas Massalas

TITLE
Director of Business Development

Chuck Smith

TITLE
Chief Operating Officer of Red Dice Holdings

George Anastassov

TITLE
Member of Advisory Board and Chief Executive Officer of Canchew Biotechnologies
AGE
55

Raul Elizalde

TITLE
President of Latin America
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Medical Marijuana board of directors in years:

4.2
Average Tenure
60
Average Age
  • The tenure for the Medical Marijuana board of directors is about average.
Board of Directors

George Anastassov

TITLE
Member of Advisory Board and Chief Executive Officer of Canchew Biotechnologies
AGE
55

Michelle Sides

TITLE
Director
TENURE
7.7 yrs

Stuart Titus

TITLE
Chairman of the Board

Philip Van Damme

TITLE
Member of Advisory Board
AGE
65

Lekhram Changoer

TITLE
Member of Advisory Board
AGE
51

Bob Cunningham

TITLE
Director
TENURE
4.2 yrs

Chris Prine

TITLE
Director
TENURE
4.2 yrs

Timothy Scott

TITLE
Director
AGE
65
TENURE
4.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Medical Marijuana's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Medical Marijuana has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MJNA News

Simply Wall St News

MJNA Company Info

Description

Medical Marijuana, Inc., an investment holding company, operates in the medical marijuana and industrial hemp markets. Its products range from patented and proprietary based cannabinoid products to seed and stalk or isolated high value extracts manufactured and formulated for the pharmaceutical, nutraceutical, and cosmeceutical industries. The company licenses its proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal cannabinoid industry. It engages in the research and development of cannabinoid-based pharmaceuticals; and marketing and distribution of cannabidiol hemp oil-based products. In addition, the company provides management support and services to cooperatives, collectives, health and wellness facilities, and medical clinics; and consulting and securities services to businesses and individuals in the legal cannabis industry. Further, it focuses on the treatment of pain and other medical disorders with the application of chewing gum-based cannabis/cannabinoid medical products. Medical Marijuana, Inc. was formerly known as Hemp Deposit Distribution Corp. and changed its name to Medical Marijuana, Inc. in March, 2011. The company was incorporated in 2003 and is headquartered in Poway, California.

Details
Name: Medical Marijuana, Inc.
MJNA
Exchange: OTCPK
Founded: 2003
$208,432,871
3,637,571,930
Website: http://www.medicalmarijuanainc.com
Address: Medical Marijuana, Inc.
12255 Crosthwaite Circle,
Poway,
California, 92064,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK MJNA Common Stock Pink Sheets LLC US USD 25. Mar 2011
Number of employees
Current staff
Staff numbers
90
Medical Marijuana employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 02:41
End of day share price update: 2019/05/17 00:00
Last earnings filing: 2019/05/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.